Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of GLPG1690 added to standard of care in idiopathic pulmonary fibrosis
2018-001406-29Phase 3Terminated
- Sponsor
- Galapagos NV
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ziritaxestat in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Galapagos NV. Primary endpoint: Rate of decline of forced vital capacity. Started Nov 2018; status: terminated.
02
Drugs
ziritaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2018-001406-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001406-29.